CERAMAX CERAMIC HIP SYSTEM
Depuy Orthopaedics, Inc. · Decision date Dec 23, 2010
What did the FDA approve?
The FDA approved the CERAMAX Ceramic Total Hip System on December 23, 2010. The approval covers noncemented use in skeletally mature individuals undergoing primary total hip replacement for rehabilitation of hips damaged by noninflammatory degenerative joint disease or its composite diagnoses of osteoarthritis, avascular necrosis, and post-traumatic arthritis.
The record identifies this as an original PMA approval, not a supplement or manufacturing notice. The device is classified as a semi-constrained metal/ceramic/ceramic/metal hip prosthesis, cemented or uncemented, under product code MRA. The statement reports the approved indication but does not provide independent evidence of safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE CERAMAX CERAMIC TOTAL HIP SYSTEM. THIS DEVICE IS INDICATED FOR NONCEMENTED USE IN SKELETALLY MATURE INDIVIDUALS UNDERGOING PRIMARY TOTAL HIP REPLACEMENT SURGERY FOR REHABILITATION OF HIPS DAMAGED AS A RESULT OF NONINFLAMMATORY DEGENERATIVE JOINT DISEASE (NIDJD) OR ANY OF ITS COMPOSITE DIAGNOSES OF OSTEOARTHRITIS, AVASCULAR NECROSIS, AND POST-TRAUMATIC ARTHRITIS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Dec 23, 2010
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P070026
- Regulatory pathway
- Premarket approval application
- Applicant
- Depuy Orthopaedics, Inc.
- Product code
- MRA
- Decision code
- APPR
- Decision date
- Dec 23, 2010
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, hip, semi-constrained, metal/ceramic/ceramic/metal, cemented or uncemented.
- Applicant
- Depuy Orthopaedics, Inc.
- Product code
- MRA
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P070026 received
Application receipt date recorded by FDA.
P070026 · FDA decision
APPR
P070026/S122 · Related supplement
CERAMAX CERAMIC HIP SYSTEM
P070026/S121 · Related supplement
CERAMAX CERAMIC HIP SYSTEM
P070026/S123 · Related supplement
Ceramax Ceramic Hip System
P070026/S118 · Related supplement
Ceramax Ceramic Total Hip System
P070026/S124 · Related supplement
Ceramax Ceramic Hip System
P070026/S125 · Related supplement
Ceramax Ceramic Hip System
P070026/S127 · Related supplement
CERAMAX CERAMIC HIP SYSTEM
P070026/S128 · Related supplement
CERAMAX Ceramic Total Hip System
P070026/S130 · Related supplement
CERAMAX Ceramic Hip System
P070026/S129 · Related supplement
CERAMAX CERAMIC HIP SYSTEM
Timeline entries are records held by MedtechLedger for P070026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CERAMAX CERAMIC HIP SYSTEMP070026/S122 | Depuy Orthopaedics, Inc. | PMA supplement | Aug 1, 2025 | FDA |
CERAMAX CERAMIC HIP SYSTEMP070026/S121 | Depuy Orthopaedics, Inc. | PMA supplement | Aug 5, 2025 | FDA |
Ceramax Ceramic Hip SystemP070026/S123 | Depuy Orthopaedics, Inc. | PMA supplement | Dec 9, 2025 | FDA |
Ceramax Ceramic Total Hip SystemP070026/S118 | Depuy Orthopaedics, Inc. | PMA supplement | Jan 8, 2026 | FDA |
Ceramax Ceramic Hip SystemP070026/S124 | Depuy Orthopaedics, Inc. | PMA supplement | Apr 10, 2026 | FDA |
Ceramax Ceramic Hip SystemP070026/S125 | Depuy Orthopaedics, Inc. | PMA supplement | Apr 29, 2026 | FDA |
CERAMAX CERAMIC HIP SYSTEMP070026/S127 | Depuy Orthopaedics, Inc. | PMA supplement | Jun 3, 2026 | FDA |
CERAMAX Ceramic Total Hip SystemP070026/S128 | Depuy Orthopaedics, Inc. | PMA supplement | Jul 24, 2026 | FDA |
CERAMAX Ceramic Hip SystemP070026/S130 | Depuy Orthopaedics, Inc. | PMA supplement | Aug 27, 2026 | FDA |
CERAMAX CERAMIC HIP SYSTEMP070026/S129 | Depuy Orthopaedics, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MRA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| HOWMEDICA OSTEONICS CORP | PMA supplement | Sep 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Depuy Orthopaedics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 700 Orthopaedic Dr., Warsaw, IN, 46582
Sources and methodology
- Original FDA record: P070026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





